We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study
Read MoreHide Full Article
RedHill Biopharma Ltd. (RDHL - Free Report) announced that it has completed enrollment in the phase II study on opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia. Top-line data from the study areexpected in the coming weeks.
A parallel global phase II/III study on orally administered opaganib for severe COVID-19 is about 50% enrolled and on track to enroll all 270 patients.Top-line data are expected in the first quarter of 2021. The study is focused on efficacy evaluation.
The company is compiling a robust data set to support the planned emergency use applications, expected as early as the next quarter. Opaganib has a unique dual anti-inflammatory and antiviral activity, which acts on the cause and effect of the COVID-19 disease with host cell targeting. This helps in minimizing thepotential for resistance due to viral mutations.
Shares of the company have soared 32.4% so far this year against the industry’s decline of 3%.
Notably, opaganib is also being evaluated in a phase IIa study for treating advanced cholangiocarcinoma and in a phase II study for addressing prostate cancer.
Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. The pharma/biotech sector is racing against time to develop treatments and vaccines for curing the contagion.
Regeneron (REGN - Free Report) initiated studies on its novel investigational antibody "cocktail" treatment REGN-COV2, which is designed to prevent and treat the SARS-CoV-2 virus. The company released first data in September 2020, which showed that REGN-COV2 reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 also showed positive trends in reducing medical visits.
Pharma giant Eli Lilly (LLY - Free Report) is also making painstaking efforts to develop several potential neutralizing antibodies for the treatment of COVID-19. In November 2020, Lilly’s antibody therapy was granted an emergency use authorization by the FDA for treating Covid-19, widening access to a treatment that early data suggest is effective in keeping people infected with coronavirus out of the hospital. Meanwhile, in October, Vir Biotechnology, Inc. (VIR - Free Report) and GlaxoSmithKline plc. announced the global expansion to phase III of the COMET-ICE study evaluating investigational monoclonal antibody, VIR-7831, for the early treatment of COVID-19 in patients who are at high risk of hospitalization.
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027. Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study
RedHill Biopharma Ltd. (RDHL - Free Report) announced that it has completed enrollment in the phase II study on opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia. Top-line data from the study areexpected in the coming weeks.
A parallel global phase II/III study on orally administered opaganib for severe COVID-19 is about 50% enrolled and on track to enroll all 270 patients.Top-line data are expected in the first quarter of 2021. The study is focused on efficacy evaluation.
The company is compiling a robust data set to support the planned emergency use applications, expected as early as the next quarter. Opaganib has a unique dual anti-inflammatory and antiviral activity, which acts on the cause and effect of the COVID-19 disease with host cell targeting. This helps in minimizing thepotential for resistance due to viral mutations.
Shares of the company have soared 32.4% so far this year against the industry’s decline of 3%.
Notably, opaganib is also being evaluated in a phase IIa study for treating advanced cholangiocarcinoma and in a phase II study for addressing prostate cancer.
Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. The pharma/biotech sector is racing against time to develop treatments and vaccines for curing the contagion.
Regeneron (REGN - Free Report) initiated studies on its novel investigational antibody "cocktail" treatment REGN-COV2, which is designed to prevent and treat the SARS-CoV-2 virus. The company released first data in September 2020, which showed that REGN-COV2 reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 also showed positive trends in reducing medical visits.
Pharma giant Eli Lilly (LLY - Free Report) is also making painstaking efforts to develop several potential neutralizing antibodies for the treatment of COVID-19. In November 2020, Lilly’s antibody therapy was granted an emergency use authorization by the FDA for treating Covid-19, widening access to a treatment that early data suggest is effective in keeping people infected with coronavirus out of the hospital. Meanwhile, in October, Vir Biotechnology, Inc. (VIR - Free Report) and GlaxoSmithKline plc. announced the global expansion to phase III of the COMET-ICE study evaluating investigational monoclonal antibody, VIR-7831, for the early treatment of COVID-19 in patients who are at high risk of hospitalization.
Zacks Rank
RedHill currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Redhill Biopharma Ltd. Price
Redhill Biopharma Ltd. price | Redhill Biopharma Ltd. Quote
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027. Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>